Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyzine SCHEMBL383277 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL3061159 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL4492 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL41450 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL491323 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL28290521 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL41448 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Etodroxizine SCHEMBL9064076 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Etodroxizine SCHEMBL668191 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL15532242 | 0.98 | DRD3 (0.95) | DRD3HRH1KCNH2CYP2D6USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 30928 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074565-A | Preparation method and application of salt-reduced processed cheese | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260109705-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2026-04-23 | — | — | US | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-4792448-A | Generic zero order controlled drug delivery system | PFIZER INC. (US) | 1988-12-20 | — | — | US | claimed |
| EP-0294993-A1 | A generic zero order controlled drug delivery system | PFIZER INC. (US) | 1988-12-14 | — | — | EP | claimed |
| US-4749700-A | NASAL ADMINISTRATION LOWER DOSAGE | NASTECH PHARMACEUTICAL CO, INC. (US) | 1988-06-07 | — | — | US | claimed |
| EP-0259113-A2 | Controlled release device for an active substance | PFIZER INC. (US) | 1988-03-09 | — | — | EP | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| US-4599359-A | POTENTIATION | Cooper, Stephen A. (US) | 1986-07-08 | — | — | US | claimed |
| WO-1984002273-A1 | ANALGESIC COMBINATIONS | SANDOZ AG (CH) | 1984-06-21 | — | — | WO | claimed |
| EP-0111456-A1 | Analgesic combinations | Cooper, Stephen A. Dr. (US) | 1984-06-20 | — | — | EP | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |